Cargando…
Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
BACKGROUND: Pancreatic cancer (PDAC) is the most lethal malignancy. New treatment options for it are urgently required. The aim was to develop an antibody–drug conjugate (ADC) targeting glypican-1 (GPC-1) as a new therapy for PDAC. METHODS: We evaluated GPC-1 expression in resected PDAC specimens an...
Autores principales: | Nishigaki, Takahiko, Takahashi, Tsuyoshi, Serada, Satoshi, Fujimoto, Minoru, Ohkawara, Tomoharu, Hara, Hisashi, Sugase, Takahito, Otsuru, Toru, Saito, Yurina, Tsujii, Shigehiro, Nomura, Taisei, Tanaka, Koji, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Nakajima, Kiyokazu, Eguchi, Hidetoshi, Yamasaki, Makoto, Mori, Masaki, Doki, Yuichiro, Naka, Tetsuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189381/ https://www.ncbi.nlm.nih.gov/pubmed/32152502 http://dx.doi.org/10.1038/s41416-020-0781-2 |
Ejemplares similares
-
Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
por: Hara, Hisashi, et al.
Publicado: (2016) -
Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
por: Sugase, Takahito, et al.
Publicado: (2018) -
Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
por: Sugase, Takahito, et al.
Publicado: (2021) -
Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
por: Harada, Emi, et al.
Publicado: (2017) -
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)